Drugs / Sasanlimab
Trials 18
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 114 trials | ||||||
| Phase 1 | NCT07206225 | Nov 2025 → Jan 2030 expected | non-invasive bladder urothelial carcinoma | Pfizer | Recruiting | No outcome recorded |
| Phase 1 | NCT06870487 | May 2025 → Apr 2026 | classic Hodgkin lymphoma, diffuse large B-cell lymphoma, head and neck squamous cell carcinoma, melanoma +2 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06974734 | May 2025 → Mar 2026 | head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06704724 | Dec 2024 → May 2026 | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06580938 | Nov 2024 → Jul 2025 | colorectal cancer, head and neck cancer, melanoma, non-small cell lung carcinoma +2 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06546553 | Sep 2024 → Oct 2025 | colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma, ovarian carcinoma +1 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06447662 | Jun 2024 → Oct 2026 expected | colorectal neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Pfizer | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06448364 | May → Aug 2024 | colorectal cancer, melanoma, non-small cell lung carcinoma, urothelial carcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06285097 | Feb 2024 → Jan 2025 | colorectal carcinoma, head and neck squamous cell carcinoma, melanoma, non-small cell lung carcinoma +3 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05259397 | Mar → Sep 2022 | urinary bladder cancer | Pfizer | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT05233436 | Feb 2022 → Oct 2023 | gastric cancer, gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma, non-small cell lung carcinoma +1 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT05061537 | Oct 2021 → Oct 2022 | colorectal cancer, head and neck cancer, hepatocellular carcinoma, melanoma +6 | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04458259 | Sep 2020 → Nov 2024 | metastatic malignant neoplasm | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT04254107 | May 2020 → Dec 2023 | cervical cancer, classic Hodgkin lymphoma, cutaneous melanoma, diffuse large B-cell lymphoma +8 | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05665361 | Apr 2024 → Jun 2027 expected | clear cell renal carcinoma, papillary renal cell carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04585815 | Nov 2020 → May 2023 | non-small cell lung carcinoma | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 22 trials | ||||||
| Phase 2 | NCT07123090 | Nov 2025 → Oct 2026 expected | clear cell renal carcinoma | Stephanie Berg | Recruiting | No outcome recorded |
| Phase 2 | NCT05241340 | Feb 2022 → Aug 2025 overdue | infiltrating bladder urothelial carcinoma | The Methodist Hospital Research Institute | Active not recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2/3 | NCT06218069 Comparator | Feb → Dec 2025 overdue | non-small cell lung carcinoma | Radboud University Medical Center | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-04-26 | Pfizer | Results Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer pfizer.com ↗ |
| 2025-01-10 | Pfizer | Results Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer pfizer.com ↗
The study met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a clinically meaningful and statistically significant improvement with sasanlimab in combination with BCG (induction and maintenance) as compared to BCG alone (induction and maintenance). |
All press releases naming this drug 2 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 19 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sasanlimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06546553 ↗ |
| Action | Inhibit | “A monoclonal antibody that blocks the interaction between PD-1 and PD-L1/ PD-L2” NCT05061537 ↗ |
| Modality | Monoclonal antibody | “Sasanlimab (a PD-1 antagonist monoclonal antibody)” NCT04585815 ↗ |
| Route | Subcutaneous | “Given via injection under the skin (subcutaneous) on Day 1 of each 21-day cycle” NCT04254107 ↗ |